Split Angle

Finance4 sources

Genmab Stock Reaches Record High After Cancer Drug Trial Success

  • Genmab's stock surged to a record high, with a 9% increase reported by Yahoo Finance.
  • The surge followed positive phase 3 trial results for an experimental ovarian cancer treatment.
  • The drug demonstrated a 50% reduction in the risk of death, according to Barron's.
  • Genmab shares experienced their largest increase in over six years, as reported by Bloomberg.
  • The positive trial results have boosted confidence in Genmab's drug development pipeline.

Timeline

  1. Genmab stock surges 9% after positive phase 3 trial results

    Genmab's stock increased by 9% following positive results from a phase 3 trial for an ovarian cancer treatment.

  2. Genmab shares surge on positive cancer study results

    Genmab's shares experienced a significant increase after the release of positive results from a late-stage trial of an experimental ovarian cancer treatment.

  3. Latest

    Genmab stock hits record high on cancer drug success

    Genmab's stock reached a record high as its experimental ovarian cancer drug demonstrated a 50% reduction in the risk of death in the trial.

Articles (4)

Genmab Stock Reaches Record High After Cancer Drug Trial Success | Split Angle